Analysis of Circulating Tumor Cells in Patients with Triple Negative Breast Cancer during Preoperative Chemotherapy

Лавров, А. В.; Zubtsova, Zh. I.; Zubtsov, D. A.; Фролова, М. А.; Ignatova, Ekaterina; Skrypnikova, M. A.; Малышева, Е. В.; Legchenko, Ekaterina; Петровский, А. В.; Utyashev, Igor; Tyulyandin, S. A.; Goldshtein, D. V.

doi:10.1007/s10517-014-2514-0

Cited by 5 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar outcomes were reported by Lavarov et al [26] when 30 patients with early and advanced triple-negative breast cancer were subjected to CTC analysis before and after neoadjuvant chemotherapy using the breast select and detect system. CTCs were examined for the expression of mucin 1 (Muc-1) and Her2 oncoproteins.…”

Section: Resultssupporting

confidence: 76%

“…Regarding the differences between primary tumor and circulating tumor cells, and the dynamic change in CTCs during the course of the disease, three studies [24][25][26] reported an increase in Her2-positive CTCs during therapy, even when the primary tumor was Her2-negative. The increase in the Her2-positive CTC population was associated with therapy resistance and disease progression.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Circulating Tumor Cells in Chemoresistant Metastatic Breast Cancer

Lisencu

Bonci

Irimie

et al. 2021

JCM

View full text Add to dashboard Cite

Breast cancer is the most frequent form of cancer among women and is one of the leading causes of death. Two routes of the metastatic process have been described: linear and parallel progression. A key factor is represented by circulating tumor cells (CTCs). CTCs detach from the primary tumor or develop from cancer stem cells (CSCs) that undergo epithelial-to-mesenchymal transition (EMT). CTCs migrate to the distant site where the reverse process occurs and a new tumor arises. One of the key problems of metastatic disease is chemoresistance, which leads to treatment failure and, eventually, death. The aim of this review is to present up-to-date data regarding the role of CTCs in chemoresistance in metastatic breast cancer (MBC) patients. A search in Cochrane Library and MEDLINE databases was performed. A total of 125 articles were identified. The results of the final 12 eligible studies revealed that CTCs having stem cell features and those with mesenchymal features are aggressive subtypes of cells that survive chemotherapy, being responsible for chemoresistance and thus for disease progression in MBC patients. The hemodynamic shear stress, alongside dynamic changes among CTCs during the disease, is also an important disease progression factor.

show abstract

Section: Resultssupporting

confidence: 76%

Section: Discussionmentioning

confidence: 99%

The Role of Circulating Tumor Cells in Chemoresistant Metastatic Breast Cancer

Lisencu

Bonci

Irimie

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Finally, 50 studies were eligible for meta-analysis (Fig. 1)4591112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657.…”

Section: Resultsmentioning

confidence: 99%

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

Yan

Cui

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Whether circulating tumor cells (CTCs) can be used as an indicator of treatment response in breast cancer (BC) needs to be clarified. We addressed this issue by a meta-analysis. PubMed, EMBase and Cochrane library databases were searched in June 2016. Effect measures were estimated as pooled risk ratio (RR), odds ratio (OR) or mean difference by fixed- or random-effect models, according to heterogeneity of included studies. In total, 50 studies with 6712 patients were recruited. Overall analysis showed that there was a significant reduction of CTC-positive rate (RR = 0.68, 95% CI: 0.61–0.76, P < 0.00001) after treatment. Subgroup analyses revealed that neoadjuvant treatment, adjuvant treatment, metastatic treatment or combination therapy could reduce the CTC-positive rate, but surgery could not; moreover, the reduction was only found in HER2+ or HER2- patients but not in the triple-negative ones. Reduction of CTC-positive rate was associated with lower probability of disease progression (OR = 0.54, 95% CI: 0.33–0.89, P = 0.01) and longer overall survival period (mean difference = 11.61 months, 95% CI: 8.63–14.59, P < 0.00001) as well as longer progression-free survival period (mean difference = 5.07 months, 95% CI: 2.70–7.44, P < 0.0001). These results demonstrate that CTC status can serve as an indicator to monitor the effectiveness of treatments and guide subsequent therapies in BC.

show abstract

“…Furthermore, our results also suggested that a CTC number of C5 is associated with a worse treatment response. Moreover, several reports revealed that the CTC phenotype is not in accordance with that of the primary tumor and that CTCs with various phenotypes possess distinct metastatic potentials [36,38]. Therefore, in consideration of the limitations of this study and to understand the clinical utility of CTC detection in breast cancer, large interventional or observational studies based on CTC subtypes should be performed in the future to generate more accurate results.…”

Section: Discussionmentioning

confidence: 93%